MA34328B1 - Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale - Google Patents

Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale

Info

Publication number: MA34328B1
Authority: MA; Morocco
Prior art keywords: therapeutic agent; renal failure; prolonged release; release against; against hypertension
Prior art date: 2010-06-25

Application number

MA35480A

Other languages

English (en)

Inventor

Takashi Shirakura

Mizuho Tamura

Yoshimasa Takahashi

Ippei Kuwahara

Original Assignee

Teijin Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-25

Filing date

2011-06-24

Publication date

2013-06-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45371556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34328(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-24 Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd

2013-06-01 Publication of MA34328B1 publication Critical patent/MA34328B1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA35480A 2010-06-25 2011-06-24 Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale MA34328B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2010145056		2010-06-25
PCT/JP2011/064569 WO2011162390A1 (fr)	2010-06-25	2011-06-24	Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale

Publications (1)

Publication Number	Publication Date
MA34328B1 true MA34328B1 (fr)	2013-06-01

Family

ID=45371556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA35480A MA34328B1 (fr)	2010-06-25	2011-06-24	Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale

Country Status (26)

Country	Link
US (1)	US20130109726A1 (fr)
EP (1)	EP2586442A4 (fr)
JP (1)	JPWO2011162390A1 (fr)
KR (1)	KR20130088755A (fr)
CN (1)	CN102958521A (fr)
AR (1)	AR082022A1 (fr)
AU (1)	AU2011270133B2 (fr)
BR (1)	BR112012032543A2 (fr)
CA (1)	CA2803163A1 (fr)
CL (1)	CL2012003661A1 (fr)
CO (1)	CO6660504A2 (fr)
EC (1)	ECSP12012352A (fr)
MA (1)	MA34328B1 (fr)
MX (1)	MX2012015040A (fr)
MY (1)	MY160963A (fr)
NZ (1)	NZ605516A (fr)
PE (1)	PE20130241A1 (fr)
PH (1)	PH12012502487A1 (fr)
RU (1)	RU2013103366A (fr)
SG (1)	SG186798A1 (fr)
TN (1)	TN2012000568A1 (fr)
TW (1)	TW201215389A (fr)
UA (1)	UA107716C2 (fr)
UY (1)	UY33468A (fr)
WO (1)	WO2011162390A1 (fr)
ZA (1)	ZA201209388B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX361138B (es)	2010-06-16	2018-11-28	Takeda Pharmaceuticals Usa Inc	Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.
EP2613780B1 (fr)	2010-09-10	2014-11-12	Takeda Pharmaceuticals U.S.A., Inc.	Méthodes de traitement simultané à base de théophylline et de fébuxostat
AR089812A1 (es) *	2012-01-27	2014-09-17	Teijin Pharma Ltd	Agente terapeutico para la diabetes mellitus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69122084T2 (de)	1990-11-30	1997-04-03	Teijin Ltd., Osaka	2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
US6998404B2 (en) *	2001-08-08	2006-02-14	Genomed, Llc	Treatment or prevention of acute renal failure
WO2007019153A2 (fr)	2005-08-03	2007-02-15	Tap Pharmaceutical Products, Inc.	Methodes de traitement de l'hypertension
CA2619744C (fr) *	2005-08-18	2014-09-02	Teijin Pharma Limited	Formulation avec fonction de division en doses precises
MX2009004984A (es) *	2006-11-13	2009-09-23	Takeda Pharmaceuticals North A	Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
CN101658505A (zh) *	2009-09-29	2010-03-03	北京华禧联合科技发展有限公司	非布索坦的缓释制剂及其制备方法
MX361138B (es) *	2010-06-16	2018-11-28	Takeda Pharmaceuticals Usa Inc	Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.

2011
- 2011-06-24 KR KR1020127033036A patent/KR20130088755A/ko not_active Withdrawn
- 2011-06-24 MX MX2012015040A patent/MX2012015040A/es not_active Application Discontinuation
- 2011-06-24 MA MA35480A patent/MA34328B1/fr unknown
- 2011-06-24 NZ NZ605516A patent/NZ605516A/en not_active IP Right Cessation
- 2011-06-24 AU AU2011270133A patent/AU2011270133B2/en not_active Ceased
- 2011-06-24 CN CN2011800311202A patent/CN102958521A/zh active Pending
- 2011-06-24 CA CA2803163A patent/CA2803163A1/fr not_active Abandoned
- 2011-06-24 BR BR112012032543A patent/BR112012032543A2/pt not_active IP Right Cessation
- 2011-06-24 EP EP11798271.0A patent/EP2586442A4/fr not_active Withdrawn
- 2011-06-24 PE PE2012002449A patent/PE20130241A1/es not_active Application Discontinuation
- 2011-06-24 UY UY0001033468A patent/UY33468A/es not_active Application Discontinuation
- 2011-06-24 SG SG2012094645A patent/SG186798A1/en unknown
- 2011-06-24 WO PCT/JP2011/064569 patent/WO2011162390A1/fr not_active Ceased
- 2011-06-24 UA UAA201300872A patent/UA107716C2/ru unknown
- 2011-06-24 PH PH1/2012/502487A patent/PH12012502487A1/en unknown
- 2011-06-24 TW TW100122222A patent/TW201215389A/zh unknown
- 2011-06-24 US US13/806,370 patent/US20130109726A1/en not_active Abandoned
- 2011-06-24 MY MYPI2012701137A patent/MY160963A/en unknown
- 2011-06-24 AR ARP110102214A patent/AR082022A1/es unknown
- 2011-06-24 RU RU2013103366/15A patent/RU2013103366A/ru unknown
- 2011-06-24 JP JP2012521553A patent/JPWO2011162390A1/ja not_active Ceased
2012
- 2012-11-30 TN TNP2012000568A patent/TN2012000568A1/en unknown
- 2012-12-11 ZA ZA2012/09388A patent/ZA201209388B/en unknown
- 2012-12-20 CO CO12230952A patent/CO6660504A2/es unknown
- 2012-12-20 EC ECSP12012352 patent/ECSP12012352A/es unknown
- 2012-12-21 CL CL2012003661A patent/CL2012003661A1/es unknown

Also Published As

Publication number	Publication date
KR20130088755A (ko)	2013-08-08
UY33468A (es)	2012-01-31
AU2011270133A1 (en)	2013-01-10
PE20130241A1 (es)	2013-03-04
PH12012502487A1 (en)	2017-08-09
JPWO2011162390A1 (ja)	2013-08-22
UA107716C2 (ru)	2015-02-10
CO6660504A2 (es)	2013-04-30
CA2803163A1 (fr)	2011-12-29
AR082022A1 (es)	2012-11-07
NZ605516A (en)	2015-02-27
CL2012003661A1 (es)	2013-04-01
CN102958521A (zh)	2013-03-06
ECSP12012352A (es)	2013-02-28
ZA201209388B (en)	2013-08-28
EP2586442A1 (fr)	2013-05-01
US20130109726A1 (en)	2013-05-02
BR112012032543A2 (pt)	2016-11-22
TN2012000568A1 (en)	2014-04-01
TW201215389A (en)	2012-04-16
EP2586442A4 (fr)	2014-01-01
WO2011162390A1 (fr)	2011-12-29
RU2013103366A (ru)	2014-07-27
MX2012015040A (es)	2013-02-07
AU2011270133B2 (en)	2014-03-20
MY160963A (en)	2017-03-31
SG186798A1 (en)	2013-02-28

Publication	Publication Date	Title
NL301176I2 (nl)	2022-11-03	Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan
EP2241332A4 (fr)	2011-01-26	Agent thérapeutique contre le prurit
HUE037639T2 (hu)	2018-09-28	Pimavanszerin együttes beadása más szerekkel
EP3777939C0 (fr)	2023-06-07	Administration nasale
EP2170453C0 (fr)	2023-10-25	Raccord luer de sécurité
PL2190418T3 (pl)	2014-03-31	Sposób dawkowania ibuprofenu o natychmiastowym i długotrwałym uwalnianiu
EP2689177A4 (fr)	2014-09-03	Coupleur à raccord rapide doté d'un arrêt d'évacuation
BRPI0821316A2 (pt)	2015-06-16	Adaptador antioclusão para cateter
EP2637696A4 (fr)	2016-07-06	Composition à libération prolongée
BRPI0812562A2 (pt)	2019-09-24	composições terapêuticas anti-cd20 e métodos
BR112013013308A2 (pt)	2016-09-06	inalador e unidade articulada
ZA201004261B (en)	2011-02-23	Anthelmintic agents and their use
BRPI0916931A2 (pt)	2015-11-24	agentes terapêuticos
UA21886S (uk)	2011-06-10	З'єднувальний навушник
DK2144905T3 (da)	2013-03-11	Terapeutiske midler
EP2647381A4 (fr)	2015-12-23	Comprimé à désintégration orale
NL301214I2 (nl)	2023-04-19	Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
BRPI0907064A2 (pt)	2015-07-07	"métodos e sistemas"
BRPI0816789A2 (pt)	2015-03-17	Goji e inflamação
EP2558137A4 (fr)	2013-10-23	Procédés et combinaison
EP1999805A4 (fr)	2013-07-31	Accumulateur à sécurité améliorée
IL236360A0 (en)	2015-09-24	Inhalable medicine
EP2647003A4 (fr)	2014-08-06	Protection contre l'interaction humaine à l'aide de sons
BRPI0807421A2 (pt)	2014-11-11	Microrganismo recombinante
EP2628310A4 (fr)	2014-03-26	Élément d'ensemble haut-parleurs